| CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation J Deng, ES Wang, RW Jenkins, S Li, R Dries, K Yates, S Chhabra, ... Cancer discovery 8 (2), 216-233, 2018 | 581 | 2018 |
| Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids RW Jenkins, AR Aref, PH Lizotte, E Ivanova, S Stinson, CW Zhou, ... Cancer discovery 8 (2), 196-215, 2018 | 436 | 2018 |
| Clinical characteristics and outcomes of COVID-19–infected cancer patients: a systematic review and meta-analysis H Zhang, H Han, T He, KE Labbe, AV Hernandez, H Chen, V Velcheti, ... JNCI: Journal of the National Cancer Institute 113 (4), 371-380, 2021 | 215 | 2021 |
| CDK7 inhibition potentiates genome instability triggering anti-tumor immunity in small cell lung cancer H Zhang, CL Christensen, R Dries, MG Oser, J Deng, B Diskin, F Li, Y Pan, ... Cancer cell 37 (1), 37-54. e9, 2020 | 170 | 2020 |
| Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer G Giamas, A Filipović, J Jacob, W Messier, H Zhang, D Yang, W Zhang, ... Nature medicine 17 (6), 715-719, 2011 | 151 | 2011 |
| New approaches to SCLC therapy: from the laboratory to the clinic JT Poirier, J George, TK Owonikoko, A Berns, E Brambilla, LA Byers, ... Journal of Thoracic Oncology 15 (4), 520-540, 2020 | 146 | 2020 |
| In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma F Li, Q Huang, TA Luster, H Hu, H Zhang, WL Ng, A Khodadadi-Jamayran, ... Cancer discovery 10 (2), 270-287, 2020 | 142 | 2020 |
| The regulatory roles of phosphatases in cancer J Stebbing, LC Lit, H Zhang, RS Darrington, O Melaiu, B Rudraraju, ... Oncogene 33 (8), 939-953, 2014 | 109 | 2014 |
| SARS-CoV-2 spike protein interacts with multiple innate immune receptors C Gao, J Zeng, N Jia, K Stavenhagen, Y Matsumoto, H Zhang, J Li, ... BioRxiv, 2020 | 97 | 2020 |
| The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis MG Oser, AH Sabet, W Gao, AA Chakraborty, AC Schinzel, RB Jennings, ... Genes & development 33 (23-24), 1718-1738, 2019 | 80 | 2019 |
| Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: a … Q Huang, H Zhang, J Hai, MA Socinski, E Lim, H Chen, J Stebbing Oncoimmunology 7 (12), e1396403, 2018 | 69 | 2018 |
| Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy J Hai, H Zhang, J Zhou, Z Wu, T Chen, E Papadopoulos, CM Dowling, ... Clinical Cancer Research 26 (13), 3431-3442, 2020 | 50 | 2020 |
| The role of pseudokinases in cancer H Zhang, A Photiou, A Grothey, J Stebbing, G Giamas Cellular signalling 24 (6), 1173-1184, 2012 | 49 | 2012 |
| The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β1 Y Xu, H Zhang, LC Lit, A Grothey, M Athanasiadou, M Kiritsi, Y Lombardo, ... Science signaling 7 (330), ra58-ra58, 2014 | 47 | 2014 |
| The dual function of KSR1: a pseudokinase and beyond H Zhang, CY Koo, J Stebbing, G Giamas Biochemical Society transactions 41 (4), 1078-1082, 2013 | 40 | 2013 |
| NK cells mediate synergistic antitumor effects of combined inhibition of HDAC6 and BET in a SCLC preclinical model Y Liu, Y Li, S Liu, DO Adeegbe, CL Christensen, MM Quinn, R Dries, ... Cancer research 78 (13), 3709-3717, 2018 | 39 | 2018 |
| Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer CM Dowling, KER Hollinshead, A Di Grande, J Pritchard, H Zhang, ... Science advances 7 (3), eabc4897, 2021 | 38 | 2021 |
| Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma DJ Pinato, MW Brown, S Trousil, EO Aboagye, J Beaumont, H Zhang, ... British journal of cancer 120 (5), 512-521, 2019 | 37 | 2019 |
| Targeting HER2 Exon 20 Insertion–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib H Han, S Li, T Chen, M Fitzgerald, S Liu, C Peng, KH Tang, S Cao, ... Cancer research 81 (20), 5311-5324, 2021 | 36 | 2021 |
| Recent advances in preclinical models for lung squamous cell carcinoma Y Pan, H Han, KE Labbe, H Zhang, KK Wong Oncogene 40 (16), 2817-2829, 2021 | 31 | 2021 |
